Session » (1840–1861) Health Services Research Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1840

Value of Various Intra-Articular Injections for Knee Osteoarthritis Management

Abstract Number: 1841

Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort

Abstract Number: 1842

Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center

Abstract Number: 1843

Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning

Abstract Number: 1844

Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey

Abstract Number: 1845

Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases

Abstract Number: 1846

A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders

Abstract Number: 1847

Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients

Abstract Number: 1848

Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease

Abstract Number: 1849

Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration

Abstract Number: 1850

Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data

Abstract Number: 1851

Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Abstract Number: 1852

Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus

Abstract Number: 1853

Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care

Abstract Number: 1854

What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort

Abstract Number: 1855

Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

Abstract Number: 1856

Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

Abstract Number: 1857

More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)

Abstract Number: 1858

How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?

Abstract Number: 1859

Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort

Abstract Number: 1860

Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis

Abstract Number: 1861

Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.